CClinicalTrials.gg
CompletedNCT03493256BINERUpdated Feb 5, 2020

Novel BIochemical Markers for Predicting Type 2 NEurological Complications of Surgical Coronary Revascularization (BINER)

An observational study in Neurological Complication of Procedure (Disorder), sponsored by Collegium Medicum w Bydgoszczy. Completed at 1 site in Poland. Per ClinicalTrials.gov, last updated 2020-02-05.

Sponsored by Collegium Medicum w Bydgoszczy · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
100
Sex
All
01

Study summary

In this single center prospective cohort study a total of 100 patients scheduled for elective off-pump CABG will be recruited. They will be allocated to one study and one control group according to the presence or absence of postoperative type 2 neurological complications. The two groups will be compared in terms of serum concentrations of glial fibrillary acidic protein (GFAP), neuroserpin (NSP), phosphorylated axonal neurofilament subunit H (pNfH) and visinin-like protein 1 (VILIP-1) at the time of skin incision and closure as well as 24 hours and 7 days following surgery. Diagnostic performance of these markers for predicting type 2 neurological complications of off-pump CABG will be assessed.

02

Conditions studied

  • Neurological Complication of Procedure (Disorder)
03

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Sampling method
Probability sample

Study population

All participants will be recruited from patients scheduled for elective off-pump CABG at the Department of Cardiac Surgery, Dr Antoni Jurasz Memorial University Hospital, Bydgoszcz, Poland.

Inclusion criteria

  • patients scheduled for elective off-pump Coronary Artery Bypass Grafting (CABG)

Exclusion criteria

Exclusion Criteria:

  • neurological or psychiatric disorders
  • alcohol or drug abuse
  • preoperative left ventricular ejection fraction of less than 30%
  • extracranial carotid artery stenosis of more than 70%
  • scoring below age- and education-adjusted cut-off values in Mini-Mental State Examination (MMSE)
  • scoring over seven points on the subscales of the Hospital Anxiety and Depression Scale (HADS)
04

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
100 participants (actual)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • type 2 neurological complications present

    The group of patients diagnosed with postoperative cognitive dysfunction (POCD) or postoperative delirium (POD), or both concurrently.

    Other: exposure to type 2 neurological complications

  • type 2 neurological complications absent

    The group of patients without neurological complications.

Interventions

  • Otherexposure to type 2 neurological complications

    exposure to postoperative cognitive dysfunction (POCD) or postoperative delirium (POD), or both concurrently.

05

What researchers measure

Primary outcomes

  1. Assessment of serum GFAP concentration (ng/ml) changes.

    Comparison of patients with and without type 2 neurological complications in respect to changes from baseline concentration of glial fibrillary acidic protein (GFAP).

    Time frame: GFAP concentrations will be measured preoperatively (at the time of initial skin incision), at the completion of surgery (at the time of skin closure) as well as 24 hours and 7 days following off-pump Coronary Artery Bypass Grafting (CABG).

  2. Assessment of serum NSP concentration (ng/ml) changes.

    Comparison of patients with and without type 2 neurological complications in respect to changes from baseline concentration of neuroserpin (NSP).

    Time frame: NSP concentrations will be measured preoperatively (at the time of initial skin incision), at the completion of surgery (at the time of skin closure) as well as 24 hours and 7 days following off-pump Coronary Artery Bypass Grafting (CABG).

  3. Assessment of serum pNfH concentration (ng/ml) changes.

    Comparison of patients with and without type 2 neurological complications in respect to changes from baseline concentration of neuroserpin phosphorylated axonal neurofilament subunit H (pNfH).

    Time frame: pNfH concentrations will be measured preoperatively (at the time of initial skin incision), at the completion of surgery (at the time of skin closure) as well as 24 hours and 7 days following off-pump Coronary Artery Bypass Grafting (CABG).

  4. Assessment of serum VILIP-1 concentration (ng/ml) changes.

    Comparison of patients with and without type 2 neurological complications in respect to changes from baseline concentration of visinin-like protein 1 (VILIP-1).

    Time frame: VILIP-1 concentrations will be measured preoperatively (at the time of initial skin incision), at the completion of surgery (at the time of skin closure) as well as 24 hours and 7 days following off-pump Coronary Artery Bypass Grafting (CABG).

06

Study locations

1 site
  • Department of Cardiac Surgery, Dr Antoni Jurasz Memorial University Hospital
    Bydgoszcz, Kujawsko-Pomorskie 85-094, Poland
07

References and documents

Individual participant data

Plan to share: Yes — The data that support the findings of this study are available from the corresponding author upon reasonable request.

Supporting information: Study protocol, Csr

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT03493256
Lead sponsor
Collegium Medicum w Bydgoszczy
Responsible party
Krzysztof Szwed (Principal Investigator, Collegium Medicum w Bydgoszczy) — Principal investigator
First posted
Apr 10, 2018
Start date
Apr 1, 2018
Primary completion
Mar 1, 2019
Completion
Mar 1, 2019
Last update
Feb 5, 2020

Study contacts

Krzysztof Szwed, Dr
principal investigator · Department of Clinical Neuropsychology, Nicolaus Copernicus University, Collegium Medicum.

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion